Longer term For longer protocols, review trends every 3-6 months with a clinician
In recent years, IDH inhibitors targeting IDH mutants, including ivosidenib and enasidenib (Table 1), have been approved by the Food and Drug Administration to be used in patients with IDH1 or IDH2 mutant recurrent or refractory AML, respectively (Kim, 2017
For topical applications, standard concentrations range from 1% to 10%
5-Amino-1MQ selectively blocks NNMT, preventing methyl-group transfer and, in research models, helping preserve SAM and NAD availability
Combining peptide treatment with approaches that increase hair thickness (like microneedling) may produce more satisfying visual results